Safety last? Security and prosperity in the Gigabit Age?
Date
20 Feb 2018 18:00
Address
BMW Brand Store
Boulevard de Waterloo 23-24
1000 Brussels
BelgiumEvent Location
Belgium
Event Description
At this event in Brussels the Vodafone Institute will bring together economists, academics, entrepreneurs, technologists, and policymakers to discuss how we can get ahead of the game and secure a successful and safe digital future for Europe.
The next revolution in digital technology is coming. It will change how all of us live our lives, build our societies and run our economies. Everything will be connected, with unprecedented ability to analyse, monitor and interact with the world around us. Nothing will ever be quite the same again in future: homes, offices, factories, transport, healthcare – even, perhaps, the human body itself.
Much of this will be benign, enhancing lives and livelihoods in ways unimaginable to previous generations. But some of what lies ahead also presents serious and complex challenges in terms of ethics, equality and safety. Join us as we bring together leading economists, academics and entrepreneurs to discuss what’s needed to create a safe and sustainable digital future for Europe.
20 February 2018, 6:00 to 8.00 pm
BMW Brand Store, Boulevard de Waterloo 23-24, Brussels 1000
Doors open at 5.30pm, talks start at 6.00pm sharp, walking dinner to follow.
For registration, please contact Rut Rey: rut.rey(at)vodafone.com
Events of the week
Jobs
E3G ASBL
Aboca SpA Società Agricola
Fuels Europe
Department of Brain and Behavioral Sciences
EVENFLOW SRL
Public Power Corporation Belgium
European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
HYDROGEN EUROPE
European Institute of Peace
Strago Healthcare
EURACTIV News
- China harbors ship tied to North Korea-Russia arms transfers, satellite images show
- Pro-Palestine student demonstrations in US gain speed
- Poland’s Duda insists on NATO allies to spend 3% of GDP on defence
- Kyiv issues restrictions on passports for military-age men
- Supporting access to critical medicines: Viatris’ commitment in Europe [Promoted content]